Ingen internetforbindelse — viser den gemte version af siden.

bioAffinity Techn…

USUSD
← Til Screeneren

bioAffinity Technologies, Inc. (US:BIAF) — Biotechnology: Commercial Physical & Biological Resarch. Antal børser, hvor selskabets aktier handles: 1. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
bioaffinitytech.com
Investorrelationer
bioaffinitytech.com/contact/
Sektor
Health Care · Biotechnology: Commercial Physical & Biological Resarch
Hovedkontor
SAN ANTONIO, United States
Administrerende Direktør
Maria Zannes
Ansatte
57
Udestående Aktier
8.1 mio. pr. 2026-08-03
Free Float
532 257
Markedsværdi
3.69 mio. USD
Insidere
0.82%
Institutionelle Investorer
5.62%
Branche (SIC)
Services-Commercial Physical & Biological Research
P/E
underskud
FCF
−11.6 mio. USD
Gæld
36.5 t. USD
nettokasse
Indtjening og FCF — for de 12 måneder frem til 30.06.2026 (virksomhedens seneste rapport).
NAV
0.56 USD · P/NAV 6.71
Balancedato30.06.2026
Aktiver7.62 mio. USD
− Forpligtelser3.85 mio. USD
= NAV (aktiekapital i selskabets aktionærer)3.77 mio. USD
− Goodwill1.40 mio. USD
− Immaterielle Aktiver688 t. USD
= Materiel NAV1.68 mio. USD
Aktier6 783 061
NAV pr. Aktie0.56 USD
Håndgribelig NAV pr. Aktie0.25 USD
Aktiekurs (BIAF)3.7300 USD
P/NAV6.71
NAV-Historie
BalancedatoNAVNAV pr. Aktie
30.06.20263.77 mio. USD0.56 USD
31.03.20263.65 mio. USD0.81 USD
31.12.20257.28 mio. USD1.62 USD
30.09.20258.90 mio. USD2.57 USD
30.06.2025−2.14 mio. USD−0.08 USD
31.03.20251.44 mio. USD0.08 USD
31.12.20242.60 mio. USD5.01 USD
30.09.20243.12 mio. USD0.23 USD
Beskrivelse

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

annonce

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksBIAFUSD3.73 -5.81%almindelige aktier

Kurs over 3 Måneder

US:BIAF · USD
stigningsdag faldsdagHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Nyheder Denne Uge

Pressemeddelelser fra virksomhedens investorhjemmeside, opdateret dagligt. Links fører til virksomhedens hjemmeside. Overskrifterne er på originalsproget, som på virksomhedens hjemmeside.

Største Ejere

EjerAndelAktierRapportdato
ZANNES MARIA (Chief Exec…≈46.94%280 3592025-01-10
EDWARDS JAMES MICHAEL CP…≈20.11%120 1282025-01-10
ZANNES TIMOTHY PETER (Ge…≈9.17%54 7652025-01-10
REVELES XAVIER TRINIDAD…≈7.02%41 9432025-01-10
Sabby Management, LLC4.06%24 3772026-06-30
Blackrock Inc.1.1%6 5852026-06-30
Vanguard Capital Managem…0.62%3 7032026-06-30
VANGUARD INDEX FUNDS-Van…0.62%3 7032026-06-30
Geode Capital Management…0.57%3 3982026-06-30
J. Safra Sarasin Holding…0.47%2 8402026-06-30
Vanguard Fiduciary Trust…0.34%2 0712026-06-30
Susquehanna Internationa…0.3%1 7912026-06-30
Jane Street Group, LLC0.3%1 7862026-06-30
Fidelity Concord Street…0.28%1 6592026-07-31
State Street Corporation0.27%1 6062026-06-30
HRT Financial LP0.23%1 3892026-06-30
Fidelity Concord Street…0.08%5092026-07-31
Fidelity Concord Street…0.07%4342026-07-31
Fidelity Concord Street…0.03%1672026-07-31
GIRGENTI STEVEN (Officer…—1.09 mio.2025-01-10